MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2026.102610

Медицинская библиотека · Clinical genitourinary cancer · 2026

Safety Profile Comparison of Androgen Receptor Pathway Inhibitors: A Pharmacovigilance Signal Detection Analysis Using Disproportionality Methods and Age-Stratified Comparison of 37,875 FAERS Reports.

Beypınar İsmail, Kurtuluş Aziz, Balçık Onur Yazdan

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Androgen receptor pathway inhibitors (ARPIs) are prescribed across heterogeneous prostate cancer disease states, so direct comparison of adverse event reporting frequencies risks confounding by indication. We applied disproportionality signal detection and age-stratified comparisons to identify differential reporting signals across four ARPIs in the FDA Adverse Event Reporting System (FAERS).

METHODS

We analyzed 37,875 ARPI monotherapy reports (Q1 2004-Q4 2025; accessed January 14, 2026): enzalutamide (n = 29,419), apalutamide (n = 4884), darolutamide (n = 2236), abiraterone (n = 1336). Primary analyses comprised reporting proportion comparisons and disproportionality detection using Reporting Odds Ratios (ROR) and Proportional Reporting Ratios (PRR) with Evans criteria (PRR ≥ 2.0, lower 95% CI > 1.0, n ≥ 3), with Benjamini-Hochberg FDR correction across 24 comparisons. Secondary analyses included age stratification (< 65, 65-75, > 75 years) and multivariate logistic regression (drug, age, reporter type, report year, country).

RESULTS

Strong signals: apalutamide rash/skin reactions (PRR 4.25, 95% CI 3.91-4.62; ROR 4.87; n = 791) and darolutamide neuropathy (PRR 4.90, 4.00-6.01; ROR 5.12; n = 116), the latter likely confounded by concurrent docetaxel. Moderate signals: abiraterone hospitalization (PRR 1.75, 1.64-1.88) and enzalutamide fatigue/asthenia (PRR 1.58, 1.49-1.67). Death was reported in 24.12% of enzalutamide versus 11.23% of abiraterone cases, a difference highly susceptible to confounding by indication and not causally interpretable.

CONCLUSIONS

This FAERS analysis identifies hypothesis-generating differential adverse event reporting signals across ARPIs. Findings are exploratory, require prospective validation, and should not be used to establish causal drug effects or comparative safety conclusions.

Для цитирования: Beypınar İsmail, Kurtuluş Aziz, Balçık Onur Yazdan. Safety Profile Comparison of Androgen Receptor Pathway Inhibitors: A Pharmacovigilance Signal Detection Analysis Using Disproportionality Methods and Age-Stratified Comparison of 37,875 FAERS Reports.. Clinical genitourinary cancer. 2026. DOI: 10.1016/j.clgc.2026.102610.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.